Bayer AG (BAYN) Given Consensus Rating of “Buy” by Analysts

Shares of Bayer AG (FRA:BAYN) have been given an average recommendation of “Buy” by the twenty-two ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is €122.43 ($144.03).

BAYN has been the subject of several research analyst reports. Citigroup Inc. set a €130.00 ($152.94) price objective on Bayer AG and gave the company a “buy” rating in a report on Thursday, October 5th. UBS AG set a €125.00 ($147.06) price objective on Bayer AG and gave the company a “buy” rating in a report on Monday, November 6th. Independent Research GmbH set a €120.00 ($141.18) price objective on Bayer AG and gave the company a “neutral” rating in a report on Thursday, July 27th. Deutsche Bank AG set a €124.00 ($145.88) price objective on Bayer AG and gave the company a “buy” rating in a report on Monday, August 28th. Finally, Kepler Capital Markets set a €102.00 ($120.00) price objective on Bayer AG and gave the company a “neutral” rating in a report on Monday, August 28th.

Shares of Bayer AG (FRA:BAYN) traded up €1.10 ($1.29) during mid-day trading on Monday, reaching €108.65 ($127.82). The company’s stock had a trading volume of 2,019,757 shares. Bayer AG has a one year low of €86.06 ($101.25) and a one year high of €123.82 ($145.67).

ILLEGAL ACTIVITY NOTICE: This report was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://sportsperspectives.com/2017/11/20/bayer-ag-bayn-given-consensus-rating-of-buy-by-analysts.html.

Bayer AG Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer AG (FRA:BAYN)

Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply